Last reviewed 2026-04-22 · How we verify

Antimalarial monoclonal antibodies

Monoclonal antibodies that target and neutralize malaria parasites or parasite-derived antigens to prevent infection and reduce disease severity.

Monoclonal antibodies that target and neutralize malaria parasites or parasite-derived antigens to prevent infection and reduce disease severity. Used for Malaria prevention and treatment (investigational).

At a glance

Mechanism of action

These antibodies are designed to bind to specific antigens expressed by Plasmodium parasites or their mosquito vectors, blocking parasite development, transmission, or invasion of host cells. By leveraging the immune system's antibody-mediated mechanisms, they aim to provide protection against malaria infection and reduce transmission potential.

Approved indications

• Malaria prevention and treatment (investigational)

Common side effects

No common side effects on file.

Key clinical trials

• Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry
• The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
• Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer (PHASE2)
• SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
• Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge (PHASE3)
• A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE (PHASE3)
• Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.